Abstract

ABSTRACT

Objective: This study aimed to investigate the relationship between vitamin D [25(OH)] values with the language and

speech disorders in children.

Material and Methods: A total of 200 children were included in the study, comprising 124 children, with stuttering

(n=62), functional language disorder (n=40) and articulation disorder (n=22) as the patient group and a control group

of 76 healthy children. Vitamin D levels were examined in blood samples taken from both the patient group and the

control group.

Results: Serum vitamin D levels were determined as 23.68 ± 10.95 in patients with articulation disorder, 17.82 ± 8.28

in patients with functional language disorder, 23.36 ± 10.01 in patients with stuttering, and 26.01 ± 7.4 in the control

group. Serum vitamin D values were found to be statistically significantly (p<0.001) lower in children with functional

language disorder than in the healthy control group. It was observed that vitamin D decreased as the severity of the

stutter increased.

Conclusion: According to the results of this study, there can be considered to be an important connection between

vitamin D level and functional language disorder. Nevertheless, further studies are needed to confirm these findings in























children with language and speech disorders.

Keywords: Articulation disorder, Functional language disorder, Stuttering

References

  1. 1. Silverman FH.Stuttering and Other Fluency Disorders. Illinois:
  2. Waveland Press. 2004
  3. 2. Maria-Mengel MR, Martins Linhares MB. Risk factors for infant
  4. developmental problems. Rev Lat Am Enfermagem 2007;15:837–
  5. 42.
  6. 3. Samra HA, Mcgrath JM, Wehbe M. An integrated review of
  7. developmental outcomes and late-preterm birth. J Obstet Gynecol
  8. Neonatal Nurs 2011;40:399–411.
  9. 4. Hall NE. Developmental Language Disorder. Semin Pediatr Neurol
  10. 1997;4:77-85.
  11. 5. Holick MF, Chen TC. Vitamin D deficiency: a worldwide problem
  12. with health consequences. Am J Clin Nutr 2008;87:1080-6.
  13. 6. Holick MF. Vitamin D: importance in the prevention of cancers,
  14. type I diabetes, heart disease and osteoporosis. Am J Clin Nutr
  15. 2004;79:362-71.
  16. 7. Lemire JM, Archer DC. 1.25-dihydroxyvitamin D3 prevents the in vivo
  17. induction of murine experimental autoimmune encephalomyelitis. J
  18. Clin Invest 1991;87:1103-7.
  19. 8. Hanley DA, Cranney A, Jones G, Whiting SJ, Leslie WD, Cole DE,
  20. Atkinson SA, Josse RG, Feldman S, Kline GA, Rosen C. Vitamin D
  21. in adult health and disease: a review and guideline statement from
  22. Osteoporosis Canada. CMAJ 2010;182:610-8.
  23. 9. Kiraly SJ, Kiraly MA, Hawe RD, Makhani N. Vitamin D as
  24. a Neuroactive Substance:Review. Scientific World Journal
  25. 2006;26;125-139.
  26. 10. Sutherland MK, Wong L, Somerville MJ, Yoong LK, Bergeron C,
  27. Parmentier M, et al. Reduction of calbindin-24k mRNA levels in
  28. Alzheimer as compared to Huntington hippocampus. Brain Res
  29. Mol Brain Res 1993;18:32-42.
  30. 11. Schoenrock SA, Tarantino LM. Developmental vitamin D deficiency
  31. and schizophrenia: the role of animal models. Genes Brain Behav
  32. 2016;15:45-61.
  33. 12. McGrath J, Eyles D, Mowry B, Yolken R, Buka S. Low maternal
  34. vitamin D as a risk factor for schizophrenia:a pilot study using
  35. banked sera. Schizophr Res 2003;63:73-8.
  36. 13. Przybelski RJ, Binkley NC. Is vitamin D important for preserving
  37. cognition? A positive correlation of serum 25-hydroxyvitamin D
  38. concentration with cognitive function. Arch Biochem Biophys
  39. 2007;460:202-5.
  40. 14. American Psychiatric Association. Diagnostic criteria from DSM-IVTR.
  41. Washington DC: American Psychiatric Association 2000;370-
  42. 381.
  43. 15. Luu TM, Vohr BR, Schneider KC, Katz KH, Tucker R, Allan WC,
  44. et al. Trajectories of receptive language development from 3 to 12
  45. years pf age for very preterm children. Pediatrics 2009;124;333-
  46. 41.
  47. 16. Martson L, Peacock JL, Calvert SA, Greenough A, Marlow N.
  48. Factors affecting vocabulary acquisition at age 2 in children born
  49. between 23 and 28 weeks’ gestation. Dev Med Child Neurol
  50. 2007;49:591–6.
  51. 17. Mossabeb R, Wake KC, Finnegan K, Sivieri E, Abbasi S. Language
  52. development survey provides a useful screening tool for language
  53. delay in preterm infants. Clin Pediatr (Phila) 2012;51:638-44.
  54. 18. Ouma S, Suenaga M, Bölükbaşı Hatip FF, Hatip-Al-Khatib I, Tsuboi
  55. Y, Matsunaga Y. Serum vitamin D in patients with mild cognitive
  56. impairment and Alzheimer’s disease. Brain Behav 2018;8:e00936.
  57. 19. Garcion E, Wion-Barbot N, Montero-Menei CN, Berger F, Wion D.
  58. New clues about vitamin D functions in the nervous system. Trends
  59. Endocrinol Metab 2002;13:100-5.
  60. 20. Brown J, Bianco JI, McGrath JJ, Eyles DW. 1.25-Dihydroxyvitamin
  61. D3 induces nerve growth factor, promotes neurite outgrowth and
  62. inhibits mitosis in embryonic rat hippocampal neurons. Neurosci
  63. Lett 2003;343:139-43.
  64. 21. Munger KL, Zhang SM, O’Reilly E, Hernan MA, Olek MJ, Willett
  65. WC, et al. Vitamin D intake and incidence of multiple sclerosis.
  66. Neurology 2004;62;60-5.
  67. 22. Mackay-Sim A, Feron F, Eyles D, Burne T, McGrath J. 2004. Schizophrenia, vitamin D, and brain development. Int Rev Neurobiol 59:351-80.
  68. 23. Wang T, Shan L, Du L, Feng J, Xu Z, Staal WG, Jia F. Serum concentration of 25-hydroxyvitamin D in autism spectrum disorder: a systematic review and meta-analysis. Eur Child Adolesc Psychiatry 2016;25:453-4.
  69. 24. Brookes GB. Vitamin D deficiency and deafness: 1984 update. Am J Otology 1985;6:102–7.
  70. 25. Lemire J. 1,25-Dihydroxyvitamin D3-a hormone with immunomodulatory properties. Z Rheumatol 2000;59:24-7.
  71. 26. Garcion E, Thanh XD, Bled F, Teissier E, Dehouck MP, Rigault F, Bet al. 1.25-Dihydroxyvitamin D3 regulates gamma 1 transpeptidase activity in rat brain. Neurosci Lett 1996;216;183-6.
  72. 27. Garcion E, Wion-Barbot N, Montero-Menei CN, Berger F, Wion D. New clues about vitamin D functions in the nervous system. Trends Endocrinol Metab 2002;13:100-5.
  73. 28. Ludlow CL, Loucks T. Stuttering: a dynamic motor control disorder. J Fluen Disord 2003;28:273-95.
  74. 29. Pool KD, Devous MD, Freeman FJ, Watson BC, Finitzo T. Regional cerebral blood flow in developmental stutterers. Arch Neurol 1991;48:509-12.
  75. 30. Yairi E, Ambrose N. Epidemiology of stuttering: 21st century advances. J Fluency Disord 2013;38:66-87.
  76. 31. Lawrence M, Barclay DM. Stuttering: A brief review. Am Fam Physician 1998;57:2175-8.
  77. 32. Wu JC, Maguire G, Riley G, Lee A, Keator D, Tang C, Fallon J, Najafi A. Increased dopamine activity associated with stuttering, Neuroreport 1997;8:767-70.
  78. 33. Steidl L, Pesak J, Chytilova H. Stuttering and tetanic syndrome. Folia Phoniatr (Basel) 1991;43:7-12.
  79. 34. Alm PA. Copper in developmental stuttering. Folia Phoniatr Logop 2005;57:216-22.
  80. 35. Rutter MJ, Bishop D, Pine D, Scott S, Stevenson JS, Taylor EA, Thapar A. Rutter’s child and adolescent psychiatry. 5th. Hoboken (NJ): Wiley-Blackwell 2010
  81. 36. Harrison LJ, McLeod S. Risk and protective factors associated with speech and language impairment in a nationally representative sample of 4- to 5-year-old children. J Speech Lang Hear Res 2010;53:508-29.
  82. 37. Yasin A, Aksu H, Ozgür E, Ozgür BG. Speech and language delay in childhood: a retrospective chart review. ENT Updates 2017;7;22-7.

Copyright and license

Copyright © 2020 The Author(s). This is an open access article distributed under the Creative Commons Attribution License (CC BY), which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited.

How to cite

1.
Sağıroğlu S. A Comparison of Vitamin D Levels in Chidren with Language and Speech Disorders and Healthy Children in the Turkish Population. Turk J Pediatr Dis [Internet]. 2020 Mar. 18 [cited 2025 Jul. 5];14(2):158-63. Available from: https://turkjpediatrdis.org/article/view/708